RNA key in helping stem cells know what to become

July 07, 2020

Look deep inside our cells, and you'll find that each has an identical genome -a complete set of genes that provides the instructions for our cells' form and function.

But if each blueprint is identical, why does an eye cell look and act differently than a skin cell or brain cell? How does a stem cell - the raw material with which our organ and tissue cells are made - know what to become?

In a study published July 8, University of Colorado Boulder researchers come one step closer to answering that fundamental question, concluding that the molecular messenger RNA (ribonucleic acid) plays an indispensable role in cell differentiation, serving as a bridge between our genes and the so-called "epigenetic" machinery that turns them on and off.

When that bridge is missing or flawed, the researchers report in the journal Nature Genetics, a stem cell on the path to becoming a heart cell never learns how to beat.

The paper comes at a time when pharmaceutical companies are taking unprecedented interest in RNA. And, while the research is young, it could ultimately inform development of new RNA-targeted therapies, from cancer treatments to therapies for cardiac abnormalities.

"All genes are not expressed all the time in all cells. Instead, each tissue type has its own epigenetic program that determines which genes get turned on or off at any moment," said co-senior author Thomas Cech, a Nobel laureate and distinguished professor of biochemistry. "We determined in great detail that RNA is a master regulator of this epigenetic silencing and that in the absence of RNA, this system cannot work. It is critical for life."

Scientists have known for decades that while each cell has identical genes, cells in different organs and tissues express them differently. Epigenetics, or the machinery that switches genes on or off, makes this possible.

But just how that machinery works has remained unclear.

In 2006, John Rinn, now a professor of biochemistry at CU Boulder and co-senior-author on the new paper, proposed for the first time that RNA - the oft-overlooked sibling of DNA (deoxyribonucleic acid) - might be key.

In a landmark paper in Cell, Rinn showed that inside the nucleus, RNA attaches itself to a folded cluster of proteins called polycomb repressive complex (PRC2), which is believed to regulate gene expression. Numerous other studies have since found the same and added that different RNAs also bind to different protein complexes.

The hotly debated question: Does this actually matter in determining a cell's fate?

No fewer than 502 papers have been published since. Some determined RNA is key in epigenetics; others dismissed its role as tangential at best.

So, in 2015, Yicheng Long, a biochemist and postdoctoral researcher in Cech's lab, set out to ask the question again using the latest available tools. After a chance meeting in a breakroom at the BioFrontiers Institute where both their labs are housed, Long bumped into Taeyoung Hwang, a computational biologist in Rinn's lab.

A unique partnership was born.

"We were able to use data science approaches and high-powered computing to understand molecular patterns and evaluate RNA's role in a novel, quantitative way," said Hwang, who along with Long is co-first-author on the new paper.

In the lab, the team then used a simple enzyme to remove all RNA in cells to understand whether the epigenetic machinery still found its way to DNA to silence genes. The answer was 'no.'

"RNA seemed to be playing the role of air traffic controller, guiding the plane - or protein complex - to the right spot on the DNA to land and silence genes," said Long.

For a third step, they used the gene-editing technology known as CRISPR to develop a line of stem cells destined to become human heart muscle cells but in which the protein complex, PRC2, was incapable of binding to RNA. In essence, the plane couldn't connect with air-traffic control and lost its way, and the process fell apart.

By day 7, the normal stem cells had begun to look and act like heart cells. But the mutant cells didn't beat. Notably, when normal PRC2 was restored, they began to behave more normally.

"We can now say, unequivocally, that RNA is critical in this process of cell differentiation," said Long.

Previous research has already shown that genetic mutations in humans that disrupt RNA's ability to bind to these proteins boost risk of certain cancers and fetal heart abnormalities. Ultimately, the researchers envision a day when RNA-targeted therapies could be used to address such problems.

"These findings will set a new scientific stage showing an inextricable link between epigenetics and RNA biology," said Rinn. "They could have broad implications for understanding, and addressing, human disease going forward."
-end-


University of Colorado at Boulder

Related Stem Cell Articles from Brightsurf:

Fat cell hormone boosts potential of stem cell therapy
Mesenchymal stem cell (MSC) therapy has shown promising results in the treatment of conditions ranging from liver cirrhosis to retinal damage, but results can be variable.

Oncotarget Characterization of iPS87, a prostate cancer stem cell-like cell line
Oncotarget Volume 11, Issue 12 reported outside its natural niche, the cultured prostate cancer stem cells lost their tumor-inducing capability and stem cell marker expression after approximately 8 transfers at a 1:3 split ratio.

Stem cell identity unmasked by single cell sequencing technology
Scientists from The University of Queensland's Diamantina Institute have revealed the difference between a stem cell and other blood vessel cells using gene-sequencing technology.

It's all about the (stem cell) neighborhood
Researchers at Duke-NUS Medical School have now identified how the stem cell neighbourhood, known as a niche, keeps stem cells in the gut alive.

Spaceflight activates cell changes with implications for stem cell-based heart repair
A new study of the effects of spaceflight on the development of heart cells identified changes in calcium signaling that could be used to develop stem cell-based therapies for cardiac repair.

Not just a stem cell marker
The protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.

Interferon-beta producing stem cell-derived immune cell therapy on liver cancer
Induced pluripotent stem (iPS) cell-derived myeloid cells (iPS-ML) that produce the anti-tumor protein interferon-beta (IFN-beta) have been produced and analyzed by researchers from Kumamoto University, Japan.

Scientists aim to create the world's largest sickle cell disease stem cell library
Scientists at the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine are creating an induced pluripotent stem cell (iPSC)-based research library that opens the door to invaluable sickle cell disease research and novel therapy development.

Designer switches of cell fate could streamline stem cell biology
Researchers at the University of Wisconsin-Madison have developed a novel strategy to reprogram cells from one type to another in a more efficient and less biased manner than previous methods.

Allen Institute for cell science releases gene edited human stem cell lines
The Allen Institute for Cell Science has released the Allen Cell Collection: the first publicly available collection of gene edited, fluorescently tagged human induced pluripotent stem cells that target key cellular structures with unprecedented clarity.

Read More: Stem Cell News and Stem Cell Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.